Abstract: Cervical cancer is an important disease burden of women in the world. The persistent infection of high-risk HPV（HR-HPV） is one of major factors of cervical cancer. At present，the major methods of cervical cancer screening in the United States are the cervical cytology testing and the co-screening with cytology and HR-HPV testing. HR-HPV testing alone could be one of the primary screening methods for cervical cancer, which is proposed by the 2015 American Interim Clinical Guidance. HR-HPV testing alone could be a alternative strategy for the cytology testing and the co-screening. We herein interpret the background，main content and evidence of this guidance.

Key words: Uterine cervical neoplasms, Papillomaviridae, Cytodiagnosis, Guidebooks